following an abbreviated submission:
zanubrutinib (Brukinsa®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Zanubrutinib offers an additional treatment choice in the therapeutic class of Bruton’s tyrosine kinase inhibitors (BTKi).
Another BTKi was accepted for use under the end of life and ultra-orphan process.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice289KB (PDF)
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2819
- Indication:
As monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 August 2025